When AI designs a drug, who gets the credit?
When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think…
What happened
When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think…
Why it matters
The launch may affect adoption and competitive positioning for AI; usage evidence is the next signal to watch.
Affected entities
View evidence
1 reports · 1 original report · 1 independent
- MIT Technology ReviewPrimary source · Supports · EN · 100%When AI designs a drug, who gets the credit? ↗
Claims
- When AI designs a drug, who gets the credit? Observed
Conflicts
No material conflict detected in the available evidence.
Timeline
- First reported
Market move following event
Market reaction is not yet available for this asset and time window.